State-specific issues have emerged from the broader healthcare and public policy ecosystem—this session will delve into how cleverly-titled legislation, like “Prescription Drug Affordability Boards” (PDABs), might change the funding landscape, for better or worse, and how patient advocates can engage meaningfully both pre- and post-legislation.